J&J Unit Stops Fulranumab Development; Returns Rights

Johnson & Johnson unit Janssen has halted development of the osteoarthritis candidate fulranumab.

The company says the decision was based on strategic portfolio prioritization rather than safety concerns. It added that it is returning all rights to fulranumab to Amgen and terminating the license agreement.